Q&A: Poolbeg Pharma’s Jeremy Skillington on AI-led RSV breakthrough
Episode 1750, Dec 20, 2023, 10:29 AM
(Watch the video interview HERE)
Jeremy Skillington, CEO of Poolbeg Pharma #POLB, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates
00:28 Details of the latest results of lab-based analysis of RSV drug candidates.
01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery.
2:41 The importance of the data quality offered by human challenge models in lab-base analysis.
4:35 The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.
Jeremy Skillington, CEO of Poolbeg Pharma #POLB, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates
00:28 Details of the latest results of lab-based analysis of RSV drug candidates.
01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery.
2:41 The importance of the data quality offered by human challenge models in lab-base analysis.
4:35 The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.